secwatch.observer — SEC 8-K summary
======================================

Issuer:     VYNE Therapeutics Inc. (VYNE)
CIK:        0001566044
Form:       8-K
Filed at:   2023-02-10T23:59:59+00:00
Accession:  0001104659-23-018639
Event type: other_material
Sentiment:  negative
Materiality: 0.65
Item codes: 3.03, 5.03, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

VYNE Therapeutics completes 1:18 reverse stock split, reducing shares to ~3.25M
-------------------------------------------------------------------------------

- 1:18 reverse stock split effective Feb 10, 2023; shares outstanding drop from 58.5M to ~3.25M.
- Board approved final ratio on Feb 8; stockholders authorized range 1:10–1:25 at Jan 12 special meeting.
- No fractional shares issued; cash payments in lieu. Trading on split-adjusted basis begins Feb 13, 2023.
- CUSIP changes to 92941V 308; all stock options and warrants adjusted proportionally with higher exercise price.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1566044/000110465923018639/0001104659-23-018639-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1566044/000110465923018639/tm236109d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-23-018639

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer